Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday

MrDecoder · 2026-03-25T22:18:34+00:00

Corcept Therapeutics' shares surged nearly 20% following FDA approval of Lifyorli for treating certain ovarian cancers. The approval was based on positive trial results, signaling potential for future successes in the biotech sector.

MrDecoder

2026-03-25 22:18:34

Abstract generation in progress

Corcept Therapeutics (CORT +19.66%) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its shares leaped skyward on the news. By the end of the day, they had risen by almost 20% in value.

The FDA says yes to Lifyorli

Corcept announced that the U.S. Food and Drug Administration (FDA) approved its Lifyorli, in combination with the chemotherapy drug nab-paclitaxel, for the treatment of the platinum-resistant stages of ovarian, fallopian tube, and primary peritoneal cancer. The approval covers adults who have previously been administered one to three prior systemic treatment regimens.

Image source: Getty Images.

According to the company, the FDA’s green light was based on the encouraging outcomes of Lifyorli’s Rosella trial. This involved 381 patients who were administered the combination therapy, or Lifyorli alone.

Corcept focuses on therapies involving the modulation of cortisol, the so-called “stress hormone” that regulates a number of the body’s functions. It’s clearly going to continue pursuing that strategy. The company quoted CEO Joseph Belanoff as saying that “Today’s approval of Lifyorli is an important first step, but there is much more to explore with this new mode of treatment.”

Expand

NASDAQ: CORT

Corcept Therapeutics

Today’s Change

(19.66%) $6.65

Current Price

$40.47

Key Data Points

Market Cap

$3.6B

Day’s Range

$33.99 - $50.40

52wk Range

$28.66 - $117.33

Volume

12M

Avg Vol

2.3M

Gross Margin

98.30%

Betting on future wins

One advantage of the biotech sector is that its victories can be clear and significant. This isn’t Corcept’s first time at the rodeo (it received its first FDA approval in 2012), but Lifyorli’s win not only gives the company a high-potential product in the cancer segment, but it also validates its unique focus on cortisol. I have no trouble imagining more approvals for the biotech in the coming years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.